Nautilus Biotechnology Inc - Asset Resilience Ratio
Nautilus Biotechnology Inc (NAUT) has an Asset Resilience Ratio of 53.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NAUT total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Nautilus Biotechnology Inc's Asset Resilience Ratio has changed over time. See NAUT net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Nautilus Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NAUT market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $107.55 Million | 53.53% |
| Total Liquid Assets | $107.55 Million | 53.53% |
Asset Resilience Insights
- Very High Liquidity: Nautilus Biotechnology Inc maintains exceptional liquid asset reserves at 53.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nautilus Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Nautilus Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Nautilus Biotechnology Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Nautilus Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.12% | $102.25 Million | $242.74 Million | -8.28pp |
| 2023-12-31 | 50.41% | $154.02 Million | $305.56 Million | +30.42pp |
| 2022-12-31 | 19.98% | $69.95 Million | $350.05 Million | -20.20pp |
| 2021-12-31 | 40.18% | $160.11 Million | $398.45 Million | -7.03pp |
| 2020-12-31 | 47.21% | $40.13 Million | $85.01 Million | -39.42pp |
| 2019-12-31 | 86.64% | $16.06 Million | $18.54 Million | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more